The Food and Drug Administration has recently approved a new Parkinson’s treatment manufactured by AbbVie. The treatment is called Duopa and is a combination of two compounds called levodopa and carbidopa.
The new Parkinson’s treatment is the first of its kind to be effective for 16 hours. Previous oral formulations for Parkinson’s disease do not last more than four hours after a single administration.
Duopa, the latest Parkinson’s treatment is now available in Canada and can be administered via a small infusion pump, delivering it to the patient’s small intestine.
One of the lead investigators of the new Parkinson’s treatment, Dr. C. Warren Olanow said that as the Parkinson’s disease advances in a patient, it affects the motor features and they can be very difficult to control. Dr. Olanow, who is a professor at Mount Sinai School of Medicine, said of the new Duopa treatment that it showed to significantly reduce the amount of off time the patients with advanced Parkinson’s experience.
AbbVie’s executive vice president, Michael Severino, said that the new treatment’s approval by the FDA means an important milestone for AbbVie. Severino, who is also chief scientific officer at AbbVie added that the new drug is important for patients with advanced Parkinson’s disease because it will help them with their motor symptoms.
Parkinson’s disease is a condition characterized by a reduced level of dopamine in the brain which affects the motor system, leading to poor mobility, stiffness and slowness.
Most of patients who have been diagnosed with Parkinson’s disease are treated with levodopa. This drug has a limited effectiveness and if taken excessively it can lead to involuntary body movements, a condition known as dyskinesia.
Last week, the FDA approved another drug for treating Parkinson’s disease manufactured by Impax Laboratories, called Rytary. The drug has been rejected twice prior to its approval last week.
Other companies that have developed approved Parkinson’s treatments include Cynapsus Therapeutics, Acorda Therapeutics and NeuroDerm.
Duopa will be available as 100 mL single-use cassettes that contain 4.63 mg of cardiopa and 20 mg of levedopa per 1mL of enteral suspension in 7 count cartons.
According to recent reports, approximately 1 million Americans have Parkinson’s disease.
Image Source: vogue.com